Prevention of hepatic metastases by liver lectin blocking with D-galactose in colon cancer patients. A prospectively randomized clinical trial.
76 colon adenocarcinoma patients (stages 1-3, NO, MO) were enrolled into a prospectively randomized clinical trial, 39 patients were perioperatively treated with D-galactose-(therapy group: 1.9 g/kg BW and day) or D-glucose-containing electrolyte infusions (control group: n = 37). There were no cases of perioperative mortality. The complication rate was 17.1% (therapy group: 15.3%; control group: 18.9%). Since tumor staging and grading were equally distributed for therapy and control groups, a non-stratified statistical analysis yielded a) significantly reduced hepatic metastases and b) improved overall survival for patients of the therapy group. Stage-dependent analysis demonstrated that stage 3 carcinoma patients of the treatment group developed significantly less hepatic metastases as compared to patients of the control group.
Warczynski
P
P
MMA Postgraduate Medical School Warsaw, Poland.
Gil
J
J
Szmigielski
S
S
Beuth
J
J
Pulverer
G
G
D000230:Adenocarcinoma / Q000188:drug therapy*; D000328:Adult; D000368:Aged; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D005690:Galactose / Q000627:therapeutic use*; D006801:Humans; D037102:Lectins / Q000037:antagonists & inhibitors*; D008113:Liver Neoplasms / Q000517:prevention & control* / Q000556:secondary*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies
D037102:Lectins; D005690:Galactose